Form 4: Akoya Biosciences COO Frederic Pla Reports Stock Transactions

Frederic Pla, COO of Akoya Biosciences, reports acquisition of shares and stock options, as well as shares withheld for taxes.

Summary

• On February 22, 2024, Frederic Pla, the Chief Operating Officer of Akoya Biosciences, acquired 35,000 shares of common stock.
• These shares were acquired as restricted stock units, vesting in four equal annual installments starting March 1, 2025.
• On the same day, Pla also acquired options to purchase 70,000 shares of common stock at an exercise price of $5.35, vesting over time.
• On March 1, 2024, 2,049 shares of common stock were disposed of to cover taxes on a previously granted restricted stock unit award at a price of $6.03.
• Following these transactions, Pla directly owns 103,506 shares of common stock and indirectly owns 20,000 shares through The Pla Family Trust dtd 8/7/14.
• Pla also directly owns options to purchase 70,000 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reflects routine stock transactions by a company executive. The acquisition of shares and options is a positive sign, but the disposal of shares for tax purposes is a neutral event.

Positives

• The acquisition of 35,000 shares and 70,000 stock options by the COO demonstrates confidence in the company's future.

Negatives

• The disposal of 2,049 shares to cover taxes, while routine, slightly reduces Pla's direct holdings.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder confidence due to the COO's increased stake in the company.

Key Dates